Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases

被引：0
|
作者：
Nejabat, Mojgan [1 ]
Hadizadeh, Farzin [2 ]
Almahmeed, Wael [3 ]
Sahebkar, Amirhossein [4 ,5 ]
机构：
[1] Mashhad Univ Med Sci, Sch Pharm, Dept Med Chem, Mashhad, Iran
[2] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Iran
[3] Cleveland Clin Abu Dhabi, Heart & Vasc Inst, Abu Dhabi, U Arab Emirates
[4] Saveetha Univ, Saveetha Med Coll & Hosp, Saveetha Inst Med & Tech Sci, Ctr Global Hlth Res, Chennai, India
[5] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Iran
来源：
DRUG DISCOVERY TODAY | 2025年 / 30卷 / 03期
关键词：
proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i); diabetes; cancer; cardiovascular; cerebrovascular; stroke; LDL-CHOLESTEROL; METAANALYSIS; PREVENTION; EFFICACY; THERAPY; PEOPLE; SAFETY; RISK; ERA;
D O I：
10.1016/j.drudis.2025.104316
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have potential applications in cancer therapy and as cholesterol-lowering treatments. The impact of PCSK9 suppression on both tumor growth and metastasis, as well as the management of diabetes, has been demonstrated. PCSK9i can also enhance outcomes and reduce cardiovascular (CV) events in individuals with a history of such events. In this review, we provide insights into the pharmacology, safety, and impact of PCSK9i. We highlight cutting-edge investigations, the development of innovative PCSK9i-based products, and a more comprehensive understanding of the potential effects of these drugs on cancer, diabetes, and CV and cerebrovascular diseases.
引用
收藏
页数：15
相关论文
共 50 条
  • [21] Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
    Giugliano, Robert P.
    Sabatine, Marc S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (24) : 2638 - 2651
  • [22] Do PCSK9 inhibitors reduce cardiovascular events?
    Kolber, Michael R.
    Nickonchuk, Tony
    Turgeon, Ricky
    CANADIAN FAMILY PHYSICIAN, 2018, 64 (09) : 669 - 669
  • [23] Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review
    Samad Azari
    Aziz Rezapour
    Negar Omidi
    Vahid Alipour
    Masoud Behzadifar
    Hossein Safari
    Masih Tajdini
    Nicola Luigi Bragazzi
    Heart Failure Reviews, 2020, 25 : 1077 - 1088
  • [24] Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review
    Azari, Samad
    Rezapour, Aziz
    Omidi, Negar
    Alipour, Vahid
    Behzadifar, Masoud
    Safari, Hossein
    Tajdini, Masih
    Bragazzi, Nicola Luigi
    HEART FAILURE REVIEWS, 2020, 25 (06) : 1077 - 1088
  • [25] PCSK9 Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues
    Zhuravleva, Marina, V
    Prokofievl, Alexey B.
    Shikh, Evgenia, V
    Serebrova, Svetlana Yu
    Gorodetskaya, Galina, I
    Demchenkova, Elena Yu
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2020, 16 (04) : 644 - 653
  • [26] In search of the pleiotropic effects of PCSK9 inhibitors
    Raber, Lorenz
    Ueki, Yasushi
    EUROINTERVENTION, 2022, 18 (08) : E609 - E610
  • [27] Effects of PCSK9 inhibitors on platelet function
    Raber, Lorenz
    Ueki, Yasushi
    EUROINTERVENTION, 2023, 18 (15) : 1215 - 1217
  • [28] High glucose effects on PCSK9 expression in aortic VSMC: role of PCSK9 inhibitors
    Barale, C.
    Melchionda, E.
    Russo, I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S421 - S421
  • [29] Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
    Panagiotopoulou, Olga
    Chiesa, Scott T.
    Tousoulis, Dimitrios
    Charakida, Marietta
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (27) : 4494 - 4521
  • [30] Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors
    Safarova, Maya S.
    Kullo, Iftikhar J.
    ATHEROSCLEROSIS, 2022, 361 : 30 - 31
12345